Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 10 of 10

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2022

Phase 1 Study of Intravitreal (IVT) Gene Therapy with ADVM-022 for neovascular AMD (OPTIC Trial): the role of neutralizing antibodies (NAbs)

Szilard Kiss; Adam Turpcu; Kristina Bender; Michael Friedman; Elinore Chung; John Han

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):306 – F0109.

ARVO Annual Meeting Abstract June 2021

Phase 1 Study of Intravitreal Gene Therapy with ADVM-022 for neovascular AMD (OPTIC Trial)

Brandon Busbee; David S Boyer; Arshad M. Khanani; Charles Clifton Wykoff; Dante Joseph Pieramici; Carl Regillo; Carl J Danzig; Brian C Joondeph; James Major; Carol Hoang; Adam Turpcu; Carol Chung; Szilard Kiss; Mehdi Gasmi; Aaron Osborne

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):352.

ARVO Annual Meeting Abstract June 2020

Phase 1 Study of Intravitreal Gene Therapy ADVM-022 for neovascular AMD (OPTIC Trial)

Arshad M. Khanani; Szilard Kiss; Adam Turpcu; Carol Hoang; Aaron Osborne

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1154.

ARVO Annual Meeting Abstract June 2015

A US Claims Analysis of Anti-VEGF Treatment Patterns in Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion, and Diabetic Macular Edema

Michelle V Carle; Kathleen Wilson; Alice Huang; David Smith; Helen Varker; Stephen S Johnston; Adam Turpcu

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1405.

ARVO Annual Meeting Abstract June 2015

Patient and provider perspectives: Why are patients with diabetes mellitus noncompliant with dilated eye exams?

Yamina Rajput; Maxine Fisher; Tao Gu; Joseph Singer; Amanda Marshall; Seonyoung Ryu; John Barron; Adam Turpcu; Catherine MacLean

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1440.

ARVO Annual Meeting Abstract April 2014

Treatment Patterns and Associated Costs of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration

Szilard Kiss; Pravin U Dugel; Kathleen Wilson; Alice Huang; David Smith; Helen Varker; Stephen S Johnston; Adam Turpcu

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5596.

ARVO Annual Meeting Abstract June 2013

Truck Drivers Suffer Significant Economic Harm Due to Diabetic Macular Edema

Sunil Patel; Colleen Peters; Kristen Garcia; Angela Jaimes; Bryce Miller; Steven Kymes; Adam Turpcu

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):2369.

ARVO Annual Meeting Abstract March 2012

The Willingness to Pay for the Prevention of Visual Impairment Among Community Members

Steven M. Kymes; Colleen M. Peters; Aimee I. James; Irwin Tran; Rajendra S. Apte; Kevin J. Blinder; Gaurav K. Shah; Jamie Kambarian; Adam Turpcu; Shoshana Colman

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):1424.

ARVO Annual Meeting Abstract March 2012

Cases of Legal Blindness and Visual Impairment Avoided Using Ranibizumab for Diabetic Macular Edema in the United States

Rohit Varma; Neil M. Bressler; Quon Doan; Paul P. Lee; Ivan J. Suner; Mark Danese; Chantal M. Dolan; Adam Turpcu; James Ward; Jason S. Ehrlich

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):5739.

ARVO Annual Meeting Abstract March 2012

The Responsiveness of the National Eye Institute Visual Function Questionniare-25 (NEI VFQ-25) to Visual Acuity Gains in Diabetic Macular Edema Patients

Adam Turpcu; Shoshana Colman; Ivan J. Suner; Neil M. Bressler; Rohit Varma; Paul Lee; Chantal Dolan; James Ward; Linda Yau

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):6346.

Advertisement